MRC Technology and AICR Partnership Reports Success for Cancer Research
News Feb 27, 2013
MRC Technology has reported successful results from the first year of its agreement with the Association for International Cancer Research (AICR).
The partnership enables AICR to take advantage of MRC Technology’s IP management, technology transfer, and drug discovery expertise, to help maximize the health benefits and revenue derived from AICR-funded research.
Over the year, MRC Technology’s experts reviewed and monitored 25 priority projects from AICR’s overall portfolio, advising on development and commercialization as appropriate.
For three of these projects, MRC Technology negotiated revenue share agreements on behalf of AICR with the universities holding the grants.
Each of these agreements reflects the value of the support given by AICR towards the success and commercialization of the research.
Mike Johnson, MRC Technology’s Director of Corporate Partnerships commented: “The success of this relationship is based on the ability of MRC Technology to add value to AICR’s mission, ensuring that research funded by the organization creates potential new health benefits wherever possible. We look forward to continuing our work with AICR, and to building similar partnerships with other charities and universities.”
Dr Helen Rippon, Head of Science at AICR commented, “We very much value our partnership with MRC Technology, and recognize their expertise in managing and commercializing IP. We are a small team at AICR, and only through our partnership with MRC Technology can we ensure that opportunities are not missed for AICR-funded research to be steered towards patient benefit. We have found their open, honest and regular communication and flexibility to be of great benefit through the past year. We look forward to continuing the relationship and further realizing returns on AICR-funded research for people affected by cancer.”
Researchers Awarded $28M for Illuminating Druggable Genome NIH GrantsNews
Researchers receive grants as part of the NIH program focused on experimental and informatics approaches to characterize understudied proteins from three gene families: ion channels, G protein-coupled receptors (GPCRs), and protein kinases.READ MORE
PhoreMost Completes $15M (£11M) Series-A Round to Enter Drug DiscoveryNews
Investment to fund expansion of operations and progression of drug target pipeline.READ MORE
Nanoparticles Derived from Tea Leaves Destroy Lung Cancer CellsNews
Nanoparticles derived from tea leaves inhibit the growth of lung cancer cells, destroying up to 80% of them, new research by a joint Swansea University and Indian team has shown.